Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.
Aripiprazole was initially approved to treat schizophrenia and later approved for bipolar mania, as a monotherapy and an adjunctive therapy (manic or mixed episodes), and for irritability associated with autism. Aripiprazole is a partial agonist at dopamine D(2) and D(3) and serotonin 5-HT(1A) receptors, and is an antagonist at 5-HT(2A) receptors. This profile, and convincing preliminary data from small-scale studies, provided the rationale for the large-scale exploration of aripiprazole for unipolar depression. Recently, three 6-week, large-scale, randomized, double-blind, placebo-controlled clinical trials demonstrated clinically meaningful efficacy for aripiprazole as an adjunctive therapy to antidepressants for treating major depressive disorder (MDD). In November 2007, aripiprazole was approved by the US FDA as an adjunctive therapy to antidepressants for treating MDD, with support from two of the above-mentioned trials. In the trials, aripiprazole was demonstrated to be safe and well tolerated, and showed a minimal trend for weight gain over the course of a 6-week treatment. The incidence of akathisia was higher than that reported in studies of patients with schizophrenia; however, most cases were mild to moderate and infrequently lead to discontinuation (5/1090 from all three trials). This comprehensive review provides an overview of the data from all three 6-week studies (including a pooled analysis) and from an unpublished 52-week, open-label extension study, to inform physicians and facilitate reasonable treatment decisions. In addition, specific issues associated with the use of aripiprazole as an adjunctive therapy in patients with MDD, including possible early treatment effect, appropriate timing of therapy initiation, appropriate dosing and duration of treatment, possible differential effect on depressive subgroups and long-term tolerability, are also discussed.
Department of Psychiatry, Bucheon St. Marys Hospital, The Catholic University of Korea College of Medicine, Bucheon, Kyounggi-Do, Republic of Korea. pae@catholic.ac.kr
Chi-Un
CU
Pae
Andy
A
Forbes
Ashwin A
AA
Patkar
D000818:Animals; D000068180:Aripiprazole; D002986:Clinical Trials as Topic; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004347:Drug Interactions; D006801:Humans; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole
J Clin Psychopharmacol. 2007 Dec;27(6):614-9
18004129
Schizophr Res. 2003 Jun 1;61(2-3):123-36
12729864
Arch Gen Psychiatry. 1988 Feb;45(2):129-37
3276282
World J Biol Psychiatry. 2002 Jan;3(1):5-43
12479086
Prim Care Companion J Clin Psychiatry. 2006;8(2):82-7
16862232
J Clin Psychiatry. 2007 Dec;68(12):1907-12
18162022
Int Clin Psychopharmacol. 2009 May;24(3):133-8
19318972
Depress Anxiety. 2000;11(2):58-65
10812530
J Clin Psychiatry. 2008 Dec;69(12):1928-36
19192475
Expert Opin Drug Saf. 2009 May;8(3):373-86
19505266
J Clin Psychiatry. 2005 Jan;66(1):85-93
15669893
Psychiatry Investig. 2008 Sep;5(3):142-7
20046357
Psychopharmacology (Berl). 2001 Dec;159(1):42-50
11797068
J Clin Psychiatry. 2007 Jun;68(6):826-31
17592905
Am J Psychiatry. 2008 Mar;165(3):342-51
18172020
Clin Ther. 2004 May;26(5):649-66
15220010
J Psychopharmacol. 2010 Apr;24(4):537-46
18832427
Psychopharmacology (Berl). 2009 Jul;204(4):627-39
19255746
J Affect Disord. 2005 May;86(1):37-45
15820269
Psychiatr Serv. 2008 Oct;59(10):1121-30
18832497
Prim Care Companion J Clin Psychiatry. 2008;10(6):440-7
19287552
J Clin Psychopharmacol. 2008 Apr;28(2):203-9
18344731
Drugs. 2004;64(15):1715-36
15257633
Int J Geriatr Psychiatry. 2007 Oct;22(10):986-91
17340654
Ann Clin Psychiatry. 2004 Oct-Dec;16(4):189-94
15702566
Psychopharmacology (Berl). 1994 Aug;115(4):441-6
7871087
J Clin Psychiatry. 2003 Sep;64(9):1057-64
14628981
Br J Clin Pharmacol. 2008 Dec;66(6):802-10
19032724
J Clin Psychiatry. 2005 Oct;66(10):1216-20
16259533
Brain Res. 1997 Mar 28;752(1-2):227-33
9106461
J Clin Psychiatry. 2002 Sep;63(9):763-71
12363115
J Clin Psychiatry. 2003 Sep;64(9):1048-56
14628980
Psychopharmacology (Berl). 2007 Apr;191(3):745-58
17265076
Neurosci Lett. 2005 Oct 28;387(3):157-61
16023290
CNS Spectr. 2006 Feb;11(2):93-102
16520686
J Clin Psychiatry. 2005 Oct;66(10):1326-30
16259548
Psychol Med. 2010 Jan;40(1):41-50
19460188
Drug Metab Dispos. 2008 Jun;36(6):1016-29
18332080
Can J Psychiatry. 2001 Jun;46 Suppl 1:38S-58S
11441771
Adv Ther. 2006 Jul-Aug;23(4):646-54
17050507
Prim Care Companion J Clin Psychiatry. 2008;10(2):91-6
18458732
J Pharmacol Sci. 2008 Nov;108(3):381-4
18987428
J Psychopharmacol. 1998;12(2):192-214
9694033
Psychopharmacol Bull. 2007;40(1):77-97
17285099
Psychiatry Res. 2007 Jan 15;149(1-3):195-200
17157390
J Affect Disord. 1999 Dec;56(2-3):171-81
10701474
J Psychopharmacol. 2008 Jun;22(4):343-96
18413657
J Clin Psychiatry. 2009 Apr;70(4):526-39
19358790
Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22
17214606
Depress Anxiety. 2007;24(7):522-6
17111388
J Clin Psychiatry. 2007;68 Suppl 3:25-9
17348764
CNS Spectr. 2009 Mar;14(3):144-54
19407711
World J Biol Psychiatry. 2007;8(2):112-22
17455104
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):744-50
18164528
Neuroimage. 2000 Oct;12(4):452-65
10988039
Int Clin Psychopharmacol. 2008 Sep;23(5):269-75
18703936
Eur J Pharmacol. 2007 Nov 28;574(2-3):103-11
17692841
J Affect Disord. 2009 Jun;115(3):439-49
19027961
J Clin Psychiatry. 2001 Jun;62(6):448-52
11465522
World J Biol Psychiatry. 2008;9(2):102-14
18428079
J Clin Psychiatry. 2009 Apr;70(4):540-9
19358791
Psychopharmacology (Berl). 1985;85(3):367-70
3923523
J Clin Psychopharmacol. 2004 Oct;24(5):507-11
15349006
Am J Psychiatry. 2000 Apr;157(4 Suppl):1-45
10767867
Am J Psychiatry. 2000 Sep;157(9):1423-8
10964858
Psychopharmacology (Berl). 2009 Sep;206(1):97-107
19517098
CNS Drugs. 2010 Mar;24(3):245-62
20155998
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1165-73
20307622
BMC Psychiatry. 2008 Aug 28;8:73
18752690
Arch Gen Psychiatry. 2003 Jul;60(7):681-90
12860772
J Clin Psychiatry. 2000 Jun;61(6):403-8
10901336
Ann Pharmacother. 2003 May;37(5):687-94
12708948
Am J Psychiatry. 2006 Jan;163(1):28-40
16390886
Ther Drug Monit. 2006 Dec;28(6):744-9
17164689
Brain Res Bull. 2007 Sep 14;74(1-3):58-65
17683790
Hum Psychopharmacol. 2009 Mar;24(2):145-52
19132712
Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327-36
596982
Ann Pharmacother. 2005 Nov;39(11):1798-807
16189284
CNS Spectr. 2009 Apr;14(4):197-206
19407731
Biol Psychiatry. 2003 Feb 1;53(3):193-203
12559651
Am J Geriatr Psychiatry. 2006 Feb;14(2):181-5
16473984
Curr Drug Metab. 2008 Jun;9(5):410-8
18537577
J Affect Disord. 2009 Sep;117(1-2):116-9
19171384
Int Clin Psychopharmacol. 2005 Jan;20(1):9-11
15602109
Am J Psychiatry. 2006 Nov;163(11):1905-17
17074942
CNS Drugs. 2008;22(5):367-88
18399707
Nord J Psychiatry. 2005;59(3):173-8
16208839
J Clin Psychiatry. 2007 Jun;68(6):843-53
17592907
J Clin Psychopharmacol. 2008 Apr;28(2):156-65
18344725
Drug Metab Pharmacokinet. 2007 Oct;22(5):358-66
17965519
Int J Neuropsychopharmacol. 2010 Feb;13(1):15-30
19341509
Biol Psychiatry. 2003 Dec 15;54(12):1330-7
14675796
Psychiatr Clin North Am. 2003 Jun;26(2):457-94, x
12778843
J Pharmacol Exp Ther. 2002 Jul;302(1):381-9
12065741
Can J Psychiatry. 2005 May;50(6):357-60
15999953
Am J Psychiatry. 1995 Oct;152(10):1500-3
7573590
J Affect Disord. 2005 May;86(1):99-104
15820277
Ann Clin Psychiatry. 2007 Jul-Sep;19(3):153-9
17729016
JAMA. 2003 Jun 18;289(23):3095-105
12813115
Eur Neuropsychopharmacol. 2005 Oct;15(5):563-71
16139174
Curr Med Chem. 2004 Feb;11(3):279-96
14965232